Gene therapy for Friedreich's ataxia

About Biointaxis

Biointaxis is a private, pre-revenue biotech developing an AAV-based gene therapy for Friedreich's ataxia, a rare, progressive neurodegenerative disease. The company leverages deep academic expertise in neurogenetics from its founders and has secured significant non-dilutive grant funding from Spanish and EU entities to advance its lead candidate. Its strategy is to de-risk the program through proof-of-concept and early clinical trials before partnering with a larger pharma company for late-stage development and commercialization.

Therapeutic Areas

Other Friedreich's ataxia Drugs